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Tension on JAM-A activates RhoA via GEF-H1 
and p115 RhoGEF
ABSTRACT Junctional adhesion molecule A (JAM-A) is a broadly expressed adhesion mole-
cule that regulates cell–cell contacts and facilitates leukocyte transendothelial migration. The 
latter occurs through interactions with the integrin LFA-1. Although we understand much 
about JAM-A, little is known regarding the protein’s role in mechanotransduction or as a 
modulator of RhoA signaling. We found that tension imposed on JAM-A activates RhoA, 
which leads to increased cell stiffness. Activation of RhoA in this system depends on PI3K-
mediated activation of GEF-H1 and p115 RhoGEF. These two GEFs are further regulated by 
FAK/ERK and Src family kinases, respectively. Finally, we show that phosphorylation of JAM-A 
at Ser-284 is required for RhoA activation in response to tension. These data demonstrate a 
direct role of JAM-A in mechanosignaling and control of RhoA and implicate Src family ki-
nases in the regulation of p115 RhoGEF.
INTRODUCTION
Adhesion molecules on the surface of endothelial cells serve as li-
gands for circulating leukocytes. Interactions between these adhe-
sion molecules and their corresponding receptors facilitate transen-
dothelial migration of the leukocytes to regions of inflammation. As 
the leukocyte crawls atop the endothelial cell, mechanical forces are 
imposed on the endothelial cell, resulting in activation of the small 
GTPase RhoA and an increase in cell stiffness (Liu et al., 2010; Stroka 
and Aranda-Espinoza, 2011; Heemskerk et al., 2014; Lessey-
Morillon et al., 2014; Schaefer and Hordijk, 2015). In a similar man-
ner, homodimerization of adhesion molecules at cell–cell contacts 
regulates zone-specific contractility through regulation of RhoA 
(Nelson et al., 2004; Bazellieres et al., 2015; Priya et al., 2015).
RhoA, like other small GTPases, cycles between a GTP-bound, 
active state and a GDP-bound, inactive state. Addition of GTP is 
regulated by guanine nucleotide exchange factors (GEFs), whereas 
hydrolysis of GTP to GDP, which inactivates the protein, is promoted 
by GTPase-activating proteins (GAPs; Marjoram et al., 2014). When 
activated, RhoA promotes actomyosin-based contractility, thus reg-
ulating cytoskeletal organization (Chrzanowska-Wodnicka and 
Burridge, 1996). Recent work has demonstrated that mechanical 
force, in the form of tension, imposed on individual adhesion mol-
ecules is sufficient to activate RhoA (Zhao et al., 2007; Guilluy et al., 
2011b; Collins et al., 2012; Lessey-Morillon et al., 2014; Schaefer 
et al., 2014; Barry et al., 2015; Bazellieres et al., 2015). Of interest, 
the kinetics of RhoA activation and its associated GEFs is unique for 
individual adhesion molecules, implying pathway specificity and a 
spatiotemporal response.
Junctional adhesion molecule A (JAM-A) belongs to the immu-
noglobulin (Ig) superfamily of adhesion molecules. Originally de-
scribed as a platelet receptor (Naik et al., 1995), the protein is also 
expressed on endothelial and epithelial cells, as well as in most leu-
kocyte subsets (Martin-Padura et al., 1998). JAM-A participates in a 
number of cellular functions, including formation and maintenance 
of cell–cell contacts (Martin-Padura et al., 1998; Aurrand-Lions et al., 
2001b), is a reovirus receptor (Barton et al., 2001; Campbell et al., 
2005), and is a ligand for the leukocyte-expressed LFA-1integrin di-
mer (Ostermann et al., 2002). At cell–cell contacts, JAM-A forms cis- 
and trans-homodimers (Severson et al., 2008; Monteiro et al., 2014), 
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interactions with LFA-1, JAM-A is recognized as a critical regulator of 
leukocyte transendothelial migration, and mice lacking endothelial 
expression of JAM-A display impaired immune responses (Woodfin 
et al., 2009; Lakshmi et al., 2012; Schmitt et al., 2014). It is unknown 
whether tension on JAM-A, such as that found at cell–cell contacts 
or imposed by a crawling leukocyte, can be mechanically transmit-
ted to support RhoA activation.
The work described here shows that tension on JAM-A activates 
RhoA, which results in increased cell stiffness. Activation of RhoA is 
mediated by GEF-H1 and p115 RhoGEF in a phosphoinositide 3-ki-
nase (PI3K)–dependent manner. Tension on JAM-A activates focal 
adhesion kinase (FAK) and extracellular signal-regulated kinase 
(ERK) to control GEF-H1, whereas p115 RhoGEF is regulated by Src 
family kinases (SFKs). Finally, activation of RhoA in response to ten-
sion on JAM-A requires phosphorylation of S284 on the protein’s 
C-terminus. These data demonstrate that JAM-A supports tension-
induced outside-in signaling to control RhoA and increase cellular 
stiffness.
RESULTS
Tension imposed on JAM-A activates RhoA via P13K
Tension imposed on cell surface receptors regulates cellular stiffness 
through activation of RhoA (Matthews et al., 2006; Guilluy et al., 
2011b; Collins et al., 2012; Lessey-Morillon et al., 2014). To deter-
mine whether JAM-A could support similar signaling responses, we 
used models of continuous and pulsatile force as outlined in 
Figure 1. Paramagnetic beads coated with a monoclonal antibody 
that recognizes the first Ig-like domain of JAM-A (Mandell et al., 
2004) were added to cells, and pulsatile forces were applied using 
magnetic tweezers. Cell stiffening was determined by measuring 
bead displacement using single-particle 
analysis between successive pulling events. 
Alternatively, continuous force was gener-
ated on JAM-A by suspending a magnet in 
parallel to the cells and followed by bio-
chemical analysis.
We first wanted to determine whether 
forces through JAM-A activated RhoA. Ten-
sion on anti–JAM-A coated beads increased 
RhoA activity, whereas addition of beads 
alone had no effect (Figure 2A). As a control, 
tension on poly-l-lysine (PLL)–coated beads 
did not activate RhoA (Figure 2B). Quantifi-
cation of RhoA activation in response to ten-
sion on JAM-A or PLL is shown in Figure 2, 
C and D, respectively. Previous reports also 
showed that tension on PLL does not acti-
vate RhoA (Collins et al., 2012) or increase 
cell stiffness in response to force (Collins 
et al., 2012; Barry et al., 2015). Because ten-
sion on JAM-A increased RhoA activity, we 
determined the effect on cell stiffness. Ten-
sion imposed on JAM-A increased cell stiff-
ness, as evidenced by decreased bead dis-
placement between pulse 1 and subsequent 
pulses (Figure 2E). As seen in Figure 2, F 
and G, inhibition of RhoA or Rho-associated 
protein kinase (Rho-associated, coiled-coil–
containing protein kinase [ROCK]) pre-
vented the decrease in bead displacement. 
These data indicate that tension on JAM-A 
activates RhoA to regulate cell stiffness.
which have been implicated in supporting tension between cells 
(Bazellieres et al., 2015; Tornavaca et al., 2015). These signaling 
events require the protein’s short C-terminus, which contains a PDZ-
binding domain and at least two phosphorylation sites (Severson 
and Parkos, 2009; Iden et al., 2012; Naik et al., 2014). Through its 
FIGURE 1: Overview of tension models. Cells were grown on 
fibronectin-coated substratum, and anti-JAM-A–coated paramagnetic 
beads were added at approximately a 3:1 bead-to-cell ratio. For 
application of pulsatile forces, the pole tip of a magnetic tweezers 
was lowered to 25 μm above the bead and force applied using a 
defined regimen. Bead displacement was imaged at 30 frames/s, and 
bead movement was tracked using custom software as described in 
Materials and Methods. For application of continuous force, a magnet 
was suspended parallel to the apical surface of the cells for the 
determined time. Cells were then lysed and processed for 
biochemical analysis as needed.
FIGURE 2: Tension on JAM-A activates RhoA to increase cell stiffness. RhoA activity was 
measured using RBD-pull-down assays on untreated HUVECs, HUVECs treated with anti-
JAM-A–coated beads, HUVECs with the same beads plus 3 min of continuous force (A), or the 
same regimen with PLL-coated beads (B). Data are representative of at least three separate 
experiments and are quantified as means ± SEM in C and D. *p < 0.01 vs. untreated as 
determined by t test. To determine cell stiffness, HUVECs were untreated (E) or treated with 
1 mg/ml C3 transferase for 60 min (F) or 10 μM Y-27632 for 30 min (G) before force application 
on anti-JAM-A–coated magnetic beads with magnetic tweezers. *p < 0.01 vs. pulse 1 as 
determined by t test.
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data demonstrate that force on JAM-A acti-
vates RhoA in a PI3K-dependent manner.
Tension imposed on JAM-A activates 
GEF-H1 and p115 RhoGEF to regulate 
RhoA activity
Rho family GTPases are regulated by the 
activity of GEFs and GAPs (Schmidt and 
Hall, 2002; Lessey et al., 2012). To deter-
mine which GEFs were activated in re-
sponse to tension imposed on JAM-A, we 
used a nucleotide-free RhoA pull-down as-
say (Garcia-Mata et al., 2006; Guilluy et al., 
2011a). As seen in Figure 4, A and B, ten-
sion imposed on JAM-A increased the ac-
tivity of GEF-H1 (ARHGEF2) and p115 Rho-
GEF (ARHGEF1) but not that of LARG, 
p190 RhoGEF, or PDZ RhoGEF. To deter-
mine whether GEF-H1 and p115 RhoGEF 
were responsible for RhoA activation in re-
sponse to tension on JAM-A, we knocked 
down the expression of these GEFs indi-
vidually or together. As seen in Figure 5, A 
and B, small interfering RNA (siRNA)–medi-
ated knockdown of GEF-H1 and p115 Rho-
GEF individually did not prevent RhoA acti-
vation in response to tension on JAM-A. 
However, knockdown of both GEFs con-
comitantly prevented RhoA activation in 
this system. Of importance, knockdown of 
GEF-H1 and/or p115 RhoGEF did not alter 
JAM-A expression levels.
Because inhibition of PI3K blocked acti-
vation of RhoA downstream of tension on 
JAM-A, we next investigated the protein’s 
role in the activation of GEF-H1 and p115 
RhoGEF. As seen in Figure 5, C and D, inhi-
bition of Akt with the inhibitor LY294002 pre-
vented activation of the two GEFs. These 
data demonstrate that tension on JAM-A 
activates GEF-H1 and p115 RhoGEF, both of 
which are required for RhoA activation, all of 
which occur downstream of PI3K activation.
Tension imposed on JAM-A activates GEF-H1 through FAK/
ERK and p115 RhoGEF through Src family kinases
We next wanted to determine what pathways were leading to GEF-
H1 and p115 RhoGEF activation downstream of tension on JAM-A. 
Previous reports showed that GEF-H1 can be activated downstream 
of FAK/ERK signaling in response to mechanical forces (Fujishiro 
et al., 2008; Guilluy et al., 2011b; Collins et al., 2012). To determine 
whether a similar pathway was operating in our system, we exam-
ined phosphorylation of FAK and ERK in response to tension on 
JAM-A and found increased phosphorylation of both proteins 
(Figure 6A). As shown in Figure 6B, the upstream inhibitor of ERK, 
U0126 (mitogen-activated protein kinase kinase [MEK] inhibitor), 
and FAK inhibitor 14 both inhibited GEF-H1 but had no effect on 
p115 RhoGEF activation. These results are quantified in Figure 6, C 
(GEF-H1) and D (p115 RhoGEF).
It was reported that p115 RhoGEF can be activated down-
stream of JAK2 and protein kinase Cα (PKCα; Guilluy et al., 2010; 
Peng et al., 2011), and so we examined the involvement of these 
Previous studies showed that tension imposed on some ad-
hesion molecules activates RhoA via phosphoinositide 3 kinase 
(PI3K; Collins et al., 2012), and recent reports indicate that JAM-
A regulates PI3K signaling (Nava et al., 2011; Tuncay et al., 
2015). To determine whether PI3K participated in signaling in 
response to tension on JAM-A, we assessed colocalization be-
tween beads and the PI3K sensor green fluorescent protein 
(GFP)–Akt-PH in the presence or absence of force. Tension im-
posed on JAM-A recruited GFP-Akt-PH but not GFP alone to the 
beads, indicating activation of PI3K (Figure 3, A and B). No re-
cruitment of GFP-Akt-PH occurred around PLL beads in the pres-
ence or absence of force. To confirm that PI3K was activated in 
response to force on JAM-A, we examined phosphorylation of 
Akt. As seen in Figure 3C, tension imposed on JAM-A rapidly 
increased phosphorylation of Akt. We next wanted to see 
whether PI3K signaling was required for activation of RhoA. As 
seen in Figure 3, D and E, the PI3K inhibitor LY294002 prevented 
RhoA activation downstream of force on JAM-A. Together these 
FIGURE 3: JAM-A activates PI3K upstream of RhoA. HUVECs were transfected with GFP or 
GFP-Akt-PH and incubated with anti-JAM-A– or PLL–coated magnetic beads in the presence or 
absence of 1 min of continuous force. Cells were fixed with paraformaldehyde, and enrichment of 
GFP to the area around the bead was determined. (A) Representative images. (B) Quantification. 
Data are mean ± SEM of >25 cells/experiment from three independent experiments. *p < 0.05 
vs. control by t test. HUVECs were incubated with anti–JAM-A beads, and force was applied for 
0–10 min. Akt phosphorylation, used as a marker of PI3K activation, was determined by Western 
blot (C). RhoA activity in response to force on JAM-A–coated beads was measured in HUVECs 
with or without incubation with the PI3K inhibitor LY294002 (10 μM, 30 min). (D) Representative 
blots. (E) Means ± SEM from four experiments. *p < 0.05 vs. control by t test.
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JAM-A phosphorylation is regulated by direct and global 
mechanical forces
JAM-A is phosphorylated at S285 in mice (S284 in humans) when 
the protein is localized to tight junctions (Iden et al., 2012). Be-
cause tight junctions are regions of high RhoA activity (Priya et al., 
2015), we hypothesized that increased tension on JAM-A homodi-
mers within these zones could regulate this phosphorylation 
event. To test this hypothesis, we examined JAM-A phosphoryla-
tion in response to tension on anti-JAM-A beads. Phosphorylation 
of JAM-A S284 increases rapidly in response to tension on JAM-A 
(Figure 8A). We next tested to see whether this response was spe-
cific to tension on JAM-A or was a general response to mechanical 
forces. With fluid shear stress as a model, JAM-A S284 phosphory-
lation rapidly increased before returning to levels at or below 
baseline within 30 min of shear stress onset (Figure 8B). These 
data demonstrate that JAM-A phosphorylation is stimulated by 
mechanical forces.
JAM-A phosphorylation controls RhoA activation 
in response to tension
To determine whether S284 phosphorylation is required for RhoA 
activation in response to force on JAM-A, we generated a phos-
phodeficient S284A mutant and expressed it along with empty vec-
tor and wild-type JAM-A in CHO cells that lack endogenous JAM-
A. Wild-type human JAM-A expressed in CHO-K1 cells is 
phosphorylated at S284 (Figure 9A), indicating that the necessary 
molecular components to control this modification are present. 
Further, expression of wild-type but not S284A JAM-A increased 
kinases in the activation of p115 RhoGEF in response to tension on 
JAM-A. As seen in Figure 7A, neither inhibition of JAK2 with AG 
490 nor inhibition of PKCα with Gö6976 prevented p115 RhoGEF 
activation in response to tension on JAM-A. To further confirm that 
PKCα was not required for p115 RhoGEF activation in response to 
tension on JAM-A, we used siRNA to knock down expression of 
the protein. As seen in Supplemental Figure S1, knockdown of 
PKCα did not prevent p115 RhoGEF activation in response to ten-
sion on JAM-A. Other candidates for activating p115 RhoGEF are 
the SFKs, which are known to be activated by mechanical tension 
(Kostic and Sheetz, 2006; Guilluy et al., 2011b). Inhibition of SFKs 
with Su6656 caused a significant reduction in p115 RhoGEF activa-
tion in response to tension on JAM-A (Figure 7, A and B). These 
data demonstrate that tension on JAM-A regulates GEF-H1 via 
FAK/ERK and p115 RhoGEF via SFKs.
FIGURE 4: Tension on JAM-A activates GEF-H1 and p115 RhoGEF via 
PI3K. HUVECs were exposed to anti-JAM-A–coated beads, and 
tension was imposed with a permanent magnet for 3 min. Activation 
of RhoA GEFs was determined using the GST-RhoAG17A pull-down 
assay. (A) Representative Western blots. (B) Means ± SEM from at 
least three experiments. White bars are untreated control, gray bars 
are bead only, and black bars are beads plus 3 min of tension. To test 
for a role of PI3K in activation of GEFs, some cells were treated with 
LY294002 (10 μM, 30 min) before addition of beads. GEF activity was 
assessed using GST-RhoAG17A pull-down assay as described as 
methods (C). (D) White bars are bead only, gray bars are beads plus 3 
min of tension, black bars are LY294002 plus beads, and checkered 
bars are LY29004 plus beads with tension for 3 min. Statistical analysis 
was conducted by t test.
FIGURE 5: JAM-A–mediated RhoA activation requires both GEF-H1 
and p115 RhoGEF. HUVECs were transfected with control siRNA or 
oligos designed against GEF-H1or p115 Rho GEF. Transfected cells 
were incubated with anti-JAM-A–coated magnetic beads, and some 
cells were exposed to force for 3 min. RhoA activity was determined 
by GST-RBD pull down. Representative Western blots (A) and 
quantifications (B) from six separate experiments. *p < 0.05 vs. no 
force sample for each condition as determined by t test.
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JAM-A is phosphorylated at S284 through 
the actions of PKCζ (Iden et al., 2012). Previ-
ous reports showed that PKCζ is regulated 
by mechanical forces (Disatnik et al., 2002; 
Suzuma et al., 2002; Heo et al., 2011), is 
regulated via PI3K (Mas et al., 2003; Sarkar 
et al., 2006), and controls RhoA activity in 
some systems (Dovas et al., 2006). Therefore 
we investigated a role for PKCζ in activation 
of RhoA downstream of tension on JAM-A. 
As seen in Figure 10A, tension imposed on 
JAM-A increased phosphorylation of PKCζ. 
To test for a role in RhoA activation, we used 
a short-peptide inhibitor of PKCζ to block 
downstream signaling. As seen in Figure 
10B, inhibition of PKCζ prevented RhoA acti-
vation in response to force on JAM-A. Simi-
larly, inhibition of PKCζ prevents cell stiffen-
ing in response to force on JAM-A.
DISCUSSION
Before this study, a role for JAM-A in mecha-
nosignaling was unknown. As diagrammed 
in Figure 11, we have shown that tension on 
JAM-A activates RhoA to control cell stiff-
ness (Figure 2). Activation of RhoA in this 
system requires PI3K (Figure 3) and the 
combined activities of GEF-H1 and p115 
RhoGEF (Figures 4 and 5). Activation of 
GEF-H1 depends on FAK/ERK (Figure 6), 
whereas activation of p115 RhoGEF de-
pends on SFKs (Figure 7). Tension imposed 
on JAM-A or exposure to shear stress in-
creases phosphorylation of JAM-A at S284 
(Figure 8). Phosphorylation of JAM-A at 
S284 is required for activation of RhoA and 
increased cell stiffness in response to ten-
sion on the protein (Figure 9). Finally, PKCζ 
is required for activation of RhoA in re-
sponse to force on JAM-A (Figure 10). 
Together these results identify JAM-A as a 
direct transducer of mechanical force, which 
activates RhoA to regulate cell stiffness.
JAM-A exists in cells as monomers and cis- and trans-homodi-
mers. At cell–cell junctions, JAM-A homodimers control barrier dy-
namics (Aurrand-Lions et al., 2001a; Severson et al., 2008; Monteiro 
et al., 2014). Regulation of barrier function requires interactions be-
tween JAM-A’s extracellular domain as well as binding partner inter-
actions mediated by the protein’s C-terminal PDZ-binding domain 
(Monteiro and Parkos, 2012). As a monomer, JAM-A has been 
shown to inhibit integrin signaling (Peddibhotla et al., 2013; Naik 
et al., 2014), a function that is lost when the protein dimerizes. A 
possible explanation for the observations described here is that a 
monomeric form of JAM-A binds to the anti–JAM-A magnetic 
beads. Once placed under tension, the protein behaves as a ho-
modimer similar to those found at cell–cell junctions. When local-
ized within tight junctions, which are under high levels of tension 
(Priya et al., 2015), JAM-A is phosphorylated (Iden et al., 2012). 
Similarly, in our system, JAM-A S284 phosphorylation is rapidly in-
creased by force imposed on the protein.
Monomeric JAM-A inhibits integrin signaling through interaction 
with CD9. Peddibhotla et al. (2013) reported that induction of 
barrier function in CHO cells (Figure 9B), as previously reported 
(Iden et al., 2012), indicating functional differences between the 
mutant and wild-type protein. We first tested to see whether RhoA 
activation occurred in the JAM-A S284A mutant. Tension imposed 
on wild-type JAM-A but not on JAM-A S284A resulted in increased 
RhoA activity (Figure 9, C and D). As a control, anti-JAM-A beads 
were added to empty vector–transfected CHO cells, with no RhoA 
activation observed. Force imposed on wild-type JAM-A resulted 
in cell stiffening, whereas force imposed on cells expressing the 
S284A mutant did not (Figure 9, E and F). Attempts were made to 
measure bead displacement in empty vector–transfected cells, but 
this measurement was not possible because the beads did not at-
tach to the cell surface and were drawn to the magnetic tweezers 
instantly. Similar to what was observed in human umbilical vein en-
dothelial cells (HUVECs), cell stiffening in CHO cells could be inhib-
ited by C3-transferase and Y-27632 (Figure 9, F and G, respec-
tively), indicating that RhoA was responsible. These data 
demonstrate that JAM-A S284 phosphorylation is required for 
RhoA activation in response to tension on the protein.
FIGURE 6: GEF-H1 is activated downstream of FAK/ERK in response to tension on JAM-A. 
(A) HUVECs were incubated with anti-JAM-A–coated magnetic beads, and tension was applied 
for 0–5 min. Cells were lysed and analyzed for ERK and FAK phosphorylation by Western blot 
analysis. (B) HUVECs were incubated with anti-JAM-A–coated magnetic beads, and some cells 
were pretreated with the MEK inhibitor U0126 (25 μM) or FAK inhibitor 14 (2 μM) for 30 min 
before addition of beads, with some samples experiencing 3 min of force. RhoA GEF activity 
was assessed by GST-RhoAG17A pull-down assay. (C, D) Activation of GEF-H1 and p115 RhoGEF, 
respectively. Data are mean ± SEM from at least three experiments. *p < 0.05 vs. no-force 
control for each condition by t test.
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networks due to loss of monomer-associated signaling inhibition. 
Indeed, Tornavaca et al. (2015) showed that focal adhesions are 
more abundant in cells in which JAM-A has been knocked down. 
We observed a decrease in phosphorylation of Src at Y527, the site 
regulated by Csk, and an increase in FAK phosphorylation (Y397) in 
HUVECs in which JAM-A had been knocked down (Supplemental 
Figure S2). Increases in FAK phosphorylation in response to JAM-A 
knockdown could indicate increased RhoA activity or a disruption in 
focal adhesion turnover by regulating integrin recycling. With re-
gard to this possibility, knockdown of JAM-A could lead to activa-
tion of RhoA through activation of p115 RhoGEF. This raises the 
possibility that distinct pools of JAM-A exist to control spatiotempo-
ral control of cellular contractility. Thus loss of JAM-A–mediated 
suppression of SFKs would result in increased RhoA activity or at 
least redistribution of active RhoA. Knockdown of JAM-A could also 
lead to increased FAK phosphorylation through decreased integrin 
recycling. Indeed, previous work showed a deficiency in β1 integrin 
recycling in JAM-A–null neutrophils, resulting in impaired chemo-
taxis (Cera et al., 2009).
Previous reports demonstrated that cis- (Severson et al., 2008; 
Peddibhotla et al., 2013) and trans-dimerization (Monteiro et al., 
2014) mutants of JAM-A control the protein’s function. In our model, 
JAM-A was engaged using an antibody that recognizes the first Ig-
like domain, the region involved in dimerization. Alternatively, LFA-1 
binds JAM-A in the protein’s second Ig-like domain. Binding of 
LFA-1 to JAM-A has been shown to destabilize homophilic interac-
tions, possibly due to the fact that LFA-1/JAM-A binding can sup-
port more tension than JAM-A dimers (Wojcikiewicz et al., 2009). 
Future studies using cis- and trans-dimerization mutants engaged 
with JAM-A/fc–coupled beads, anti–JAM-A–coupled beads, and 
LFA-1 I-domain beads engaged to the same proteins would provide 
further insight into the modes of mechanical forces supported by 
JAM-A.
The data in Figure 6 demonstrate that SFKs control p115 Rho-
GEF activity. This is not surprising, because SFKs are known to be 
regulated by mechanical forces. SFK family members Fyn (Kostic 
and Sheetz, 2006; Chiu et al., 2008; Guilluy et al., 2011b; Fiore 
et al., 2015), Src (Chaturvedi et al., 2007; Wijetunge and Hughes, 
2007), Yes (Niediek et al., 2012), and Lyn (Alessandri-Haber et al., 
2008; Hughan et al., 2014) are all activated in response to mechani-
cal forces. Because SFKs are activated by force and Su6656 inhibits 
multiple SFKs (Blake et al., 2000), it is difficult to determine which 
kinase(s) are involved without extensive investigation. Fyn has been 
associated with activation of the RhoGEF LARG in response to force 
on integrins (Guilluy et al., 2011b). In our system, LARG was not 
activated in response to tension on JAM-A, but this does not neces-
sarily rule out a role for Fyn in the activation of p115 RhoGEF, as the 
ligand and cell type used were different between these studies. Pre-
vious work showed that p115 RhoGEF is activated in response to 
integrin engagement to fibronectin (Dubash et al., 2007), a process 
that likely involves a force component. Although this earlier study 
demonstrated that p115 RhoGEF was required for cell spreading 
onto fibronectin, it did not elucidate the mechanism of activation. 
Determining whether SFKs are responsible for p115 RhoGEF activa-
tion after integrin engagement will be pursued in future work.
The present findings may be relevant for several physiological 
processes. When expressed on endothelial cells, JAM-A participates 
in leukocyte transendothelial migration by binding to LFA-1. It is 
known that crawling leukocytes impose forces on endothelial cells, 
resulting in regional stiffening responses (Schaefer and Hordijk, 
2015). The present work demonstrates that forces imposed on 
JAM-A activate RhoA to elevate cell stiffness. This suggests that 
JAM-A dimers results in a disruption of a JAM-A/CD9/αvβ3 com-
plex, leading to increased cell migration. Previous work also showed 
that activation of platelets results in increased JAM-A dimerization 
and phosphorylation, as well as decreased interaction with CD9 and 
αIIbβ3 (Sobocka et al., 2004). Recently Naik et al. (2014) found that 
JAM-A inhibits αIIbβ3 by suppressing SFK signaling. In this model, 
monomeric JAM-A forms a complex with c Src-kinase (Csk) to inhibit 
integrin-Src complexes. Csk negatively regulates SFK family mem-
bers via phosphorylation of a conserved tyrosine residue in the pro-
tein’s C-terminus (Chong et al., 2005). In the context of the present 
work, tension on JAM-A would increase SFK signaling through dis-
sociation of Csk and integrins. From another perspective, decreas-
ing JAM-A expression should therefore increase similar signaling 
FIGURE 7: Src family kinases activate p115 RhoGEF in response to 
tension on JAM-A. (A) HUVECs were incubated with inhibitors against 
JAK2 (AG 490, 25 μM), PKCα (Gö6976, 10 μM), or Src family kinases 
(su6656, 5 μM) for 30 min, followed by addition of anti-JAM-A– 
coated magnetic beads. Some cells also experienced force for 3 min. 
p115 RhoGEF activity was determined by RhoAG17A pull-down assay. 
(B) Means ± SEM of at least three separate experiments *p < 0.05 vs. 
no-force control for each condition by t test.
FIGURE 8: JAM-A S284 phosphorylation is regulated by mechanical 
forces. (A) HUVECs were incubated with anti-JAM-A–coated magnetic 
beads and exposed to force for 0–10 min. (B) HUVECs were exposed 
to shear stress for 0–60 min. For both experiments, cells were lysed, 
and Western blot analysis of total and phosphorylated JAM-A was 
conducted. Blots are representative of at least three independent 
experiments
1426 | D. W. Scott et al. Molecular Biology of the Cell
JAM-A also plays a critical role when ex-
pressed at cell–cell junctions, as absence of 
the protein affects the mechanical proper-
ties of the cell (Hughan et al., 2014; 
Tornavaca et al., 2015). Breast cancer pro-
vides an intriguing model for the present 
work. There are conflicting reports on a role 
for JAM-A in breast cancer. Whereas several 
studies demonstrated that elevated JAM-A 
expression is a predictive marker for invasive 
cellular behavior and poor clinical outcomes, 
other studies reached opposite conclusions 
(Naik et al., 2008; McSherry et al., 2009; 
Murakami et al., 2011; Huang et al., 2014). 
These studies focused exclusively on total 
JAM-A expression and did not examine 
posttranslational modifications such as S284 
phosphorylation. Ebnet’s group discovered 
that JAM-A S284 phosphorylation is regu-
lated by PKCζ and PP2A (Iden et al., 2012), 
which are often dysregulated in cancer 
(Switzer et al., 2011; Seshacharyulu et al., 
2013; Yin et al., 2014). Thus cells expressing 
normal levels of JAM-A but that cannot reg-
ulate phosphorylation of the protein would 
behave similarly to cells lacking JAM-A ex-
pression. Investigating the levels of JAM-A 
phosphorylation and correlating these with 
cell behavior and clinical outcomes are fur-
ther warranted.
This article has demonstrated that ten-
sion on JAM-A activates RhoA to regulate 
cell stiffness. Activation of RhoA requires 
GEF-H1 and p115 RhoGEF, as well as phos-
phorylation of JAM-A at S284. SFKs have 
been identified as novel regulators of p115 
RhoGEF activation. It will be interesting to 
determine whether changes in JAM-A phos-
phorylation occur during diseases in vivo, 
such as in cancers of epithelial origin and in 
vascular disease. Further studies are needed 
to identify the SFKs required for p115 Rho-
GEF activation and to determine whether 
SFKs activate this GEF in other situations in 
which it is responsible for activating RhoA.
MATERIALS AND METHODS
Cell lines and reagents
HUVECs were cultured in EBM2+ BulletKit 
(cells and media from Lonza, Rockville, MD). 
CHO-K1 cells were obtained from the Ameri-
can Type Culture Collection (Manassas, VA) 
and grown in high-glucose DMEM supple-
mented with 10% fetal bovine serum and antibiotic–antimycotic solu-
tion (all from Life Technologies/ThermoFisher Scientific, Grand Island, 
NY). Y-27632 (ROCK inhibitor) was purchased from Millipore (Billerica, 
MA). Cell-permeable C3 (RhoA inhibitor) transferase was purchased 
from Cytoskeleton (Denver, CO). U0126 (MEK inhibitor), LY294002 
(PI3K inhibitor), Su6656 (Src family kinase inhibitor), AG 490 (JAK2 
inhibitor), Gö6976 (PKCα inhibitor), FAK inhibitor 14, and PKCζ pseu-
dosubstrate were from Tocris (Minneapolis, MN). All other reagents 
were from Sigma-Aldrich (St. Louis, MO) unless otherwise noted.
LFA-1/JAM-A interactions would elicit RhoA activation and promote 
leukocyte migration. A similar pathway was demonstrated for ICAM-
1, which also increases RhoA activity and cell stiffening in response 
to tension (Lessey et al., 2012). It is therefore not surprising that en-
dothelial JAM-A is required for normal leukocyte trafficking to re-
gions of inflammation (Woodfin et al., 2009; Lakshmi et al., 2012; 
Schmitt et al., 2014). Thus JAM-A and its downstream signaling net-
work could represent a novel therapeutic target for controlling in-
flammatory responses.
FIGURE 9: JAM-A S284 phosphorylation is required for RhoA activation and cell stiffening in 
response to force on JAM-A. (A) CHO cells were transfected with empty vector, JAM-A, or 
JAM-A S284A, and expression of JAM-A and phosphorylated JAM-A was determined by 
Western blot. (B) Barrier function of CHO cells expressing empty vector (EV), JAM-A, or JAM-A 
S284 was determined by FITC-dextran flux. Data are representative of three experiments run in 
triplicate. (C) CHO cells expressing EV, JAM-A, or JAM-A S284A were incubated with anti-
JAM-A–coated magnetic beads, and some cells were exposed to force for 5 min. RhoA activity 
was determined by the RBD pull-down assay. (D) Means ± SEM of four independent experiments, 
with *p < 0.05 vs. no-force control by t test. Cell stiffness was determined in cells expressing 
(E) JAM-A, (F) JAM-A S284A, (G) JAM-A and incubated with 10 μM Y-27632, or (H) expressing 
JAM-A and incubated with 1 mg/ml C3-transferase as described in Materials and Methods.
Volume 27 May 1, 2016 Tension on JAM-A activates RhoA | 1427 
(sc-17430-R) was from Santa Cruz Biotechnology (Dallas, TX). Anti-
bodies against LARG and PDZ-RhoGEF were custom produced by 
Pocono Rabbit Farms and Laboratories (Canadenesis, PA) and were 
previously described (Guilluy et al., 2011b). Anti-p190 RhoGEF was 
a generous gift of David Schlaepfer (University of California at San 
Diego, La Jolla, CA).
Application of continuous force
Magnetic beads were prepared as previously described (Lessey-
Morillon et al., 2014). Briefly, anti–JAM-A clone J10.4 (sc-53623; 
Santa Cruz Biotechnology) was conjugated to 4.5-μm tosyl-acti-
vated Dynabeads (ThermoFisher Scientific) in 0.1 M borate buffer, 
pH 9.5, according to the manufacturer’s protocol. After overnight 
incubation at 37°C with rotation, free sites were quenched by incu-
bation with 0.1% fatty acid–free bovine serum albumin (BSA) for 1 h. 
For biochemical experiments, a continuous force calculated at 
∼10 pN was applied to beads using a permanent ceramic magnetic 
(K&J Magnetics, Jamison, PA) as previously described (Guilluy et al., 
2011b).
Detection of cellular stiffening
The same beads used for the application of continuous force were 
added to cells 10 min before being engaged using the University of 
North Carolina three-dimensional force microscope. The magnetic 
tweezers pole tip was positioned 25 μm above the monolayer, and 
a force regimen of 3 s of 50-pN force followed by 4 s of no force was 
applied for repeated cycles. Bead movement was captured using a 
40× objective (Olympus UplanLN 40×/0.75) on an Olympus IX81-
ZDC2 inverted microscope (Olympus, Waltham, MA) equipped with 
a high-speed Rolera EM-C2 camera (QImaging, Surrey, BC, Canada), 
using MetaMorph software at 30 frames/s. Bead movements were 
tracked by Video Spot Tracker (http://cismm.cs.unc.edu). From 11 
to 27 beads per condition were tracked from at least two separate 
experiments. Data are presented as mean ± SEM relative to the first 
pull for each condition tested.
Shear stress
HUVECs were subjected to shear stress as previously described 
(Dardik et al., 2005). Briefly, cells were grown in six-well plates to 
siRNA, DNA constructs, and transfections
All cells were transfected using Lipofectamine 2000 (ThermoFisher 
Scientific) according to the manufacturer’s protocol. Human JAM-A 
expressed in pCDNA3.1 was previously described (Naik et al., 2001), 
and GFP-PH-Akt was a gift from Tamas Balla (Addgene plasmid 
51465). Point mutagenesis to generate S284A used the following 
primers: forward, 5′-AGAAGGTGATTTACAGCCAGCCTGCTGCCC-
GAAGTGA-3′, and reverse, 5′-TCACTTCGGGCAGCAGGCTGGCT-
GTAAATCACCTTCT-3′. siRNA target sequences are as follows: GEF-
H1 duplex 1 sense, 5′-UUUAAGAGAUCGUAGGCAA-3′; GEF-H1 
duplex 2 sense, 5′-AGACAGAGGAUGAGGCUUA-3′; p115 RhoGEF 
duplex 1 sense, 5′-GGGCUGAGGAUGAGGAUUU-3′; p115 RhoGEF 
duplex 2 sense, 5′-CCACAGAACGGGAGAAAGU-3′; JAM-A duplex 
1 sense, 5′CGAGUAAGAAGGUGAUUUA-3′; JAM-A duplex 2 sense, 
5′-AGGCGCAAGUCGAGAGGAA-3′; PKCα duplex, 5′-AAGAAG-
AAGGUGAGUACUA-3′; and control sense, 5′-UAAGGCUAUG-
AAGAGAUAC-3′.
Antibodies
The following antibodies were used for Western blot analysis: anti–
GEF-H1 (4076), anti-p115RhoGEF (3669), anti-RhoA (2117), anti–
phospho-FAK (3283), anti–phospho-Erk1/2 (4370), phospho-Akt 
(2965), FAK (3285), and ERK (9102) were purchased from Cell Sig-
naling (Danvers, MA), anti-JAM-A (612120) was from BD Transduc-
tion Laboratories (Forest Lakes, NJ), and anti–phospho-JAM-A 
FIGURE 10: Force on JAM-A regulates PKCζ to activate RhoA. 
HUVECs were incubated with anti–JAM-A beads in the presence or 
absence of forces, and PKCζ phosphorylation was determined by 
Western blot (A). HUVECs were incubated with anti-JAM-A–coated 
magnetic beads, and some cells were exposed to force for 3 min. 
Some cells had been pretreated with PKCζ inhibitory peptide. RhoA 
activity was determined by the RBD pull-down assay (B). Cell stiffness 
was determined in HUVECs after tension was imposed on anti-
JAM-A–coated beads in the presence of PKCζ inhibitor as described 
in Materials and Methods (C).
FIGURE 11: Working model of RhoA activation in response to force 
on JAM-A. Anti-JAM-A–coated magnetic beads engage JAM-A on 
the cell surface. In response to force, SFKs dissociate from the 
protein’s C-terminus. In short order, PI3K likely signals for the 
activation of PKCζ, as well as of GEF-H1 and p115 RhoGEF. Activation 
of GEF-H1 and p115 RhoGEF also requires FAK/ERK- and SFK-
mediated pathways, respectively. Finally, RhoA is activated by either 
GEF to regulate actomyosin-based cellular contractility and cell 
stiffness.
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Student’s t test between beads only and beads plus force was calcu-
lated for each construct or ligand. In all instances, p < 0.05 was 
considered significant, and all calculations were conducted in 
GraphPad Prism 5.1.
confluence, switched to 3 ml of serum-free medium for 2 h, and 
then rotated at 210 rpm for the indicated times. Lysates were col-
lected for Western blot analysis.
RhoA activity assay
Cells were lysed for analysis of RhoA (10 mM MgCl2, 500 mM NaCl, 
50 mM Tris, pH 7.6, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholate, 
1 mM phenylmethylsulfonyl fluoride [PMSF], and 10 μg/ml aprotinin 
and leupeptin) and cleared at 14,000 × g for 5 min. Lysates were 
incubated with 50 μg of glutathione-Sepharose–bound glutathione 
S-transferase (GST)–RBD (Rhotekin-binding domain) for 30 min at 
4°C with gentle rocking. Beads were then washed three times in 
50 mM Tris, pH 7.6, 10 mM MgCl2, 150 mM NaCl, 1% Triton X-100, 
1 mM PMSF, and 10 μg/ml aprotinin and leupeptin. Released pro-
teins and reserved input control were subjected to Western blot 
analysis as described later.
GEF activity assay
Active RhoA GEFs were assayed using GST-RhoA G17A as de-
scribed previously (Guilluy et al., 2011a). Cells were lysed in 150 mM 
NaCl, 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 
pH 7.6, 10 mM MgCl2, 1% Triton X-100, 1 mM PMSF, and 10 μg/ml 
aprotinin and leupeptin and incubated with 50 μg/ml glutathione-
Sepharose–bound GST-RhoAG17A for 60 min at 4°C and washed in 
the lysis buffer. Samples were then analyzed by Western blotting as 
described later.
Barrier function analysis
Cells were seeded (5 × 104 cells/well) onto fibronectin-coated 
(10 μg/ml) 0.4-μm polycarbonate Transwell membranes (Corning). 
Forty-eight hours after plating, fluorescein isothiocyanate (FITC)–
dextran (10 kDa; Sigma-Aldrich) at a final concentration of 1 mg/ml 
was added to the upper chamber. After 2 h of incubation, medium 
from the bottom chamber was collected. Medium was transferred to 
a black-walled 96-well microtiter plate (Corning), and fluorescence 
intensity was analyzed using a plate reader (excitation 485 nm, emis-
sion 520 nm; Tecan).
Western blotting
Samples were resolved on 12% (RhoA) or 8% (all other proteins) poly-
acrylamide gels (Sambrook and Russell, 2001) in the presence of 
SDS. Resolved gels were transferred onto nitrocellulose membranes, 
blocked with 5% BSA in Tris-buffered saline (25 mM Tris, pH 7.6, 
150 mM NaCl) plus 0.1% Tween-20 (TBST) and incubated with pri-
mary antibody overnight at 4°C with gentle rocking. Blots were 
washed extensively in TBST before being incubated with species-
appropriate horseradish peroxidase–conjugated secondary antibody 
(Jackson Laboratories) for 1 h at room temperature. Blots were again 
washed in TBST, and fluorescence was detected using enhanced 
chemiluminescent reagent (ThermoFisher Scientific) and x-ray film.
PI3K activation
Two days after transfection, cells were plated on fibronectin-coated 
(10 μg/ml) glass coverslips for 6 h before being incubated with 
beads. Some cells experienced force for 1 min. Cells were fixed in 
4% paraformaldehyde, and images were captured on a Zeiss Axio-
vert 200 M microscope equipped with a Hamamatsu ORCA-ERAG 
digital camera.
Statistical analysis
For analysis of cell stiffness, Student’s t test between pulse 1 and 
each subsequent pulse was calculated. For GFP-PH localization, 
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